Why the study?
Although evidence indicates crosstalk between thyroid hormones and AT1R in cardiac hypertrophy, the underlying mechanisms are poorly understood.
Does ARRB2 mediate thyroid hormone-induced cardiomyocyte hypertrophy via AT1R?
Does ARRB2 mediate thyroid hormone-induced cardiomyocyte hypertrophy via AT1R?
ARRB2 mediates thyroid hormone-induced cardiomyocyte hypertrophy via AT1R and ERK1/2 activation, highlighting a noncanonical signaling pathway in cardiac remodeling.
Hypothesis-generating for ARRB2 in T3-induced hypertrophy; leaves open translation to human cardiac remodeling.
We have previously reported that angiotensin II receptor type 1 (AT1R) contributes to the hypertrophic effects of thyroid hormones (TH) in cardiac cells. Even though evidence indicates crosstalks between TH and AT1R, the underlying mechanisms are poorly understood. Beta-arrestin (ARRB) signaling has been described as noncanonical signal transduction pathway that exerts important effects in the cardiovascular system through G-protein-coupled receptors, as AT1R. Herein, we investigated the contribution of ARRB signaling in TH-induced cardiomyocyte hypertrophy. Primary cardiomyocyte cultures were treated with Triiodothyronine (T3) to induce cell hypertrophy. T3 rapidly activates extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, which was partially inhibited by AT1R blockade. Also, ERK1/2 inhibition attenuated the hypertrophic effects of T3. ARRB2 was upregulated by T3, and small interfering RNA assays revealed the role of ARRB2-but not ARRB1-on ERK1/2 activation and cardiomyocyte hypertrophy. Corroborating these findings, the ARRB2-overexpressed cells showed increased expression of hypertrophic markers, which were attenuated by ERK1/2 inhibition. Immunocytochemistry and immunoprecipitation assays revealed the increased expression of nuclear AT1R after T3 stimulation and the increased interaction of AT1R/ARRB2. The inhibition of endocytosis also attenuated the T3 effects on cardiac cells. Our results evidence the contribution of ARRB2 on ERK1/2 activation and cardiomyocyte hypertrophy induced by T3 via AT1R.
No takes yet. Share an insight, caveat, or question.
Lino et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: